Skip to content
ClinCalc Pro
Menu
Androgen (Male Sex Hormone) Pregnancy: UK SPC §4.6: 'This medicine is intended for use by men only. This medicine is not indicated in pregnant or breast-feeding women. Pregnant women must avoid any contact with this medicine because this product may have adverse virilising effects on the foetus. In the event of inadvertent skin-to-skin contact, thoroughly wash with soap and water as soon as possible.' Fertility: 'Spermatogenesis may be reversibly suppressed with this medicine.'

Testosterone (Replacement)

Brand names: Testogel, Nebido (IM), Testim gel, Tostran gel

Testosterone replacement is used for confirmed male hypogonadism only. It is not appropriate for age-related symptoms in the absence of biochemical hypogonadism.

Adult dose

Dose: Testogel 16.2 mg/g gel in the metered pump (16.2 mg testosterone per gram; one pump actuation = 1.25 g gel = 20.25 mg testosterone) — THIS PRODUCT ONLY. Male hypogonadism (testosterone deficiency confirmed by clinical features and biochemical tests), adult and elderly men: two pump actuations of gel (40.5 mg of testosterone) applied once daily; the physician adjusts the daily dose to clinical or laboratory response in increments of one pump actuation, titrated on the pre-dose morning testosterone blood level.
Route: Transdermal — gel applied by the patient himself to clean, dry, healthy skin over both shoulders or both arms (not the genital areas)
Frequency: Once daily, at about the same time, preferably in the morning
Max: Not exceeding four pump actuations or 81 mg testosterone per day — Testogel 16.2 mg/g pump gel only; this ceiling does not apply to other testosterone products, strengths or routes
VERBATIM UK SPC §4.2 (TESTOGEL 16.2 MG/G GEL, PL283970007): 'Adult and elderly men The recommended dose is two pump actuations of gel (i.e. 40.5 mg of testosterone) applied once daily at about the same time, preferably in the morning. The daily dose should be adjusted by the physician depending on the clinical or laboratory response in individual patients, not exceeding four pump actuations or 81 mg testosterone per day. The adjustment of posology should be achieved by increments of one pump actuation of gel.' §2: 'One gram of gel contains 16.2 mg testosterone. One pump actuation delivers 1.25 g of gel containing 20.25 mg of testosterone.' §4.2 on stopping: 'Therapy should be discontinued if the blood testosterone levels consistently exceeds the normal range at the lowest daily dose of 20.25 mg (1.25 g gel, equivalent to one pump actuation) or if blood testosterone levels in the normal range cannot be achieved with the highest dose of 81 mg (5 g gel, equivalent to four pump actuations).' Before the first dose the canister pump is primed by depressing the actuator three times and discarding the first three actuations. §4.1: 'indicated in adults for testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests'. Not indicated in women; safety and efficacy under 18 years not established. SCOPE — THIS PAGE NAMES SEVERAL PRODUCTS AND ROUTES (Testogel, Nebido IM depot, Testim gel, Tostran gel); ONLY the Testogel 16.2 mg/g PUMP GEL is dosed here. Other testosterone products in the class (including the Testogel 50 mg sachet, the Nebido intramuscular depot, Testim and Tostran) have different strengths, devices and regimens and are NOT covered by this source; the figures above must not be applied to them.

Dose adjustments

Renal

UK SPC §4.2: 'Patient suffering from severe renal or hepatic insufficiency Please see section 4.4.' §4.4: 'In patients suffering from severe cardiac, hepatic or renal insufficiency, or ischaemic disease, treatment with testosterone may cause severe complications characterised by oedema with or without congestive cardiac failure. In such case, treatment must be stopped immediately. In addition, diuretic therapy may be required.' No dose figure is given.

Hepatic

UK SPC §4.2 refers severe hepatic insufficiency to §4.4: treatment with testosterone may cause severe complications characterised by oedema with or without congestive cardiac failure; in such case treatment must be stopped immediately and diuretic therapy may be required. Liver function tests should be monitored in long-term androgen therapy. No dose figure is given.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via MHRA Products — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

US labelling (FDA)

Reference — US labelling, may differ from UK

DOSAGE AND ADMINISTRATION Prior to initiating, TESTOPEL ® (testosterone pellets) confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range. The suggested dosage for androgens varies depending on the age, and diagnosis of the individual patient. Dosage is adjusted according to the patient’s response and the appearance of adverse reactions. The dosage guideline for the testosterone pellets for replacement therapy in androgen-deficient males is 150mg to 450mg subcutaneously every 3 to 6 months. Various dosage regimens have …

Source: US FDA prescribing information (openFDA / DailyMed), label dated 2025-07-17. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.

Contraindications

  • Hypersensitivity to the active substance or any of the excipients (§4.3)
  • Known or suspected prostate cancer or breast carcinoma (§4.3)

Side effects

  • Most frequent: skin reactions at the application site (erythema, acne, dry skin), anxiety and asthenia (§4.8)
  • Skin-to-skin transfer to other persons can cause inadvertent androgenisation (e.g. facial/body hair growth, voice deepening, menstrual irregularities in women, premature puberty and genital enlargement in children) (§4.4)
  • Weight gain; electrolyte changes (retention of sodium, chloride, potassium, calcium, inorganic phosphate and water) during high dose and/or prolonged treatment (§4.8)
  • Mood disorders and emotional symptoms; nervousness, depression, hostility (§4.8)
  • Hypertension; hot flushes/flushing; phlebitis (§4.8); thromboembolic events reported post-marketing (§4.4)
  • Sleep apnoea (§4.8, §4.4)
  • Gynaecomastia; increased frequency of erections, priapism, testicular pain, nipple disorder, prostate abnormalities; high-dose therapy commonly reversibly interrupts or reduces spermatogenesis, reducing the size of the testicles (§4.8)
  • Oedema; hypersensitivity reactions (§4.8)
  • Prostate cancer and hepatic neoplasm are listed as neoplasms (§4.8)
  • This side-effect list may be incomplete — check the full SPC.

Interactions

  • Oral anticoagulants: changes in anticoagulant activity (increased effect); increased monitoring of prothrombin time and INR, especially when androgens are started or stopped (§4.5)
  • ACTH or corticosteroids: increased risk of developing oedema; give cautiously in cardiac, renal or hepatic disease (§4.5)
  • Antidiabetic medication: insulin sensitivity and glycaemic control change with androgens; dose reduction might be needed (§4.5, §4.4)
  • Laboratory tests: androgens may decrease thyroxine-binding globulin, decreasing total T4 and increasing resin uptake of T3 and T4; free thyroid hormone levels remain unchanged (§4.5)

Monitoring

  • Morning pre-dose blood testosterone after steady state (usually reached by the second day) and periodically thereafter (§4.2)
  • Prostate gland and breast: digital rectal examination and serum PSA at least once yearly, and twice yearly in elderly and at-risk patients (§4.4)
  • Haemoglobin and haematocrit (polycythaemia), liver function tests and lipid profile in long-term therapy (§4.4)
  • Blood calcium in cancer patients at risk of hypercalcaemia from bone metastases (§4.4)
  • Glucose and HbA1c (§4.4)
  • Signs of excessive androgen exposure (irritability, nervousness, weight gain, prolonged or frequent erections) requiring dosage adjustment (§4.4)
  • Severe application-site reaction: re-evaluate treatment (§4.4)

Clinical monograph

How it works

It replaces endogenous testosterone, acting on androgen receptors to restore male secondary sexual characteristics and physiological androgen effects.

Prescribing in practice

  • Confirm low morning testosterone on more than one occasion before starting; it is contraindicated in prostate or male breast cancer.
  • Monitor haematocrit because of the risk of polycythaemia.
  • Assess prostate status and PSA before and during treatment.

Monitoring

Monitor testosterone levels, haematocrit and prostate health (including PSA), with clinical review of response and adverse effects.

Counselling the patient

  • This treatment is for a diagnosed testosterone deficiency, not for normal ageing.
  • Attend for blood tests to check your red cell count and prostate marker.
  • Report difficulty passing urine or other prostate symptoms.

Evidence & guidelines

Indicated for biochemically confirmed male hypogonadism per the SPC and specialist guidance.

Reference: European Association of Urology (EAU) Guidelines on Male Hypogonadism 2022; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.